Anxiety disorder


Published on

Kaplan and Sadock's Comprehensive Textbook of Psychiatry

  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Anxiety disorder

  1. 1. Generalized Anxiety Disorder• Anxiety can be conceptualized as a normal and adaptive response to threat that prepares the organism for flight or fight• Persons who seem to be anxious about almost everything, however, are likely to be classified as having generalized• anxiety disorder associated with somatic symptoms, such as muscle tension, irritability, difficulty sleeping, and restlessness
  2. 2. • The anxiety is not focused on features of another Axis I disorder, is not caused by substance use or a general medical condition, and does not occur only during a mood or psychiatric disorder.
  3. 3. Epidemiology• Generalized anxiety disorder is a common condition; reasonable estimates for its 1-year prevalence range from 3 to 8 percent.• The ratio of women to men with the disorder is about 2 to 1, but the ratio of women to men who are receiving inpatient treatment for the disorder is about 1 to 1. A lifetime prevalence is close to 5 percent with the Epidemiological Catchment Area (ECA) study suggesting a lifetime prevalence as high as 8 percent.
  4. 4. • In anxiety disorder clinics about 25 percent of patients have generalized anxiety disorder. The disorder usually has its onset in late adolescence or early adulthood, although cases are commonly seen in older adults• Also, some evidence suggests that the prevalence of generalized anxiety disorder is particularly high in primary care settings
  5. 5. Comorbidity• Generalized anxiety disorder coexists with another mental disorder, usually social phobia, specific phobia, panic disorder, or a depressive disorder• As many as 25 percent of patients eventually experience panic disorder. Generalized anxiety disorder is differentiated from panic disorder by the absence of spontaneous panic attacks.
  6. 6. Biological Factors• benzodiazepines and the azaspirones (e.g., buspirone [BuSpar]) have focused biological research efforts on the γ-aminobutyric acid and serotonin neurotransmitter systems• Benzodiazepines (which are benzodiazepine receptor agonists) are known to reduce anxiety
  7. 7. • Where as flumazenil (Romazicon) (a benzodiazepine receptor antagonist) and the β-carbolines (benzodiazepine receptor reverse agonists) are known to induce anxiety.
  8. 8. Treatment• The most effective treatment of generalized anxiety disorder is probably one that combines psychotherapeutic, pharmacotherapeutic, and supportive approaches.
  9. 9. Psychotherapy• The major techniques used in behavioral approaches are relaxation and biofeedback• Insight-oriented psychotherapy focuses on uncovering unconscious conflicts and identifying ego strengths• Psychodynamic therapy proceeds with the assumption that anxiety can increase with effective treatment. The goal of the dynamic approach may be to increase the patients anxiety tolerance (a capacity to experience anxiety without having to discharge it), rather than to eliminate anxiety
  10. 10. PharmacotherapyI. BenzodiazepinesII. BuspironeIII. VenlafaxineIV. Selective Serotonin Reuptake InhibitorsV. Other drugs
  11. 11. Anxiety Disorder due to a General Medical Condition
  12. 12. Etiology• A wide range of medical conditions can cause symptoms similar to those of anxiety disorders (Table 16.7-1). Hyperthyroidism, hypothyroidism, hypoparath yroidism, and vitamin B12 deficiency are frequently associated with anxiety symptoms• A pheochromocytoma produces epinephrine, which can cause paroxysmal episodes of anxiety symptoms
  13. 13. Generalized Anxiety• generalized anxiety disorder symptoms has been reported in patients with sjogren’s syndrome, and this rate may be related to the effects of sjogren’s syndrome on cortical and subcortical functions and thyroid function• generalized anxiety disorder symptoms in a medical disorder seems to be in Graves disease
  14. 14. Phobias• 17 percent prevalence of symptoms of social phobia in patients with Parkinsons disease• patients complain of a fear of falling, which may express itself by their being unwilling or fearful of walking
  15. 15. Differential Diagnosis• A mental status examination is necessary to determine the presence of mood symptoms or psychotic symptoms that may suggest another psychiatric diagnosis• For a clinician to conclude that a patient has an anxiety disorder caused by a general medical condition, the patient should clearly have anxiety as the predominant symptom and should have a specific causative nonpsychiatric medical disorder
  16. 16. Treatment• the removal of the primary medical condition does not reverse the anxiety disorder symptoms, treatment of these symptoms should follow the treatment guidelines for the specific mental disorder• In general, behavioral modification techniques, anxiolytic agents, and serotonergic antidepressants have been the most effective treatment modalities
  17. 17. Substance-Induced Anxiety Disorder• Substance-induced disorder is the direct result of a toxic substance, including drugs of abuse, medication, poison, and alcohol, among others.
  18. 18. Etiology• as amphetamine, cocaine, and caffeine, have been most associated with the production of anxiety disorder symptoms, many serotonergic drugs (e.g., lysergic acid diethylamide [LSD] and methylenedioxymethamphetamine [MDMA]) can also cause both acute and chronic anxiety syndromes in users• wide range of prescription medications
  19. 19. Clinical Features• Nevertheless, alcohol use disorders and other substance-related disorders are commonly associated with anxiety disorders.• Alcohol use disorders are about four times more common among patients with panic disorder than among the general population, about three and a half times more common among patients with OCD, and about two and a half times more common among patients with phobias
  20. 20. Course and Prognosis• The course and prognosis generally depend on removal of the causally involved substance and the long-term ability of the affected person to limit use of the substance.• The anxiogenic effects of most drugs are reversible.• When the anxiety does not reverse with cessation of the drug, clinicians should reconsider the diagnosis of substance-induced anxiety disorder or consider the possibility that the substance caused irreversible brain damage.
  21. 21. Treatment• anxiety disorder symptoms continue even after stopping substance use, treatment of the anxiety disorder symptoms with appropriate psychotherapeutic or pharmacotherapeutic modalities may be appropriate
  22. 22. Anxiety Disorder not Otherwise Specified
  23. 23. Mixed Anxiety-Depressive Disorder• Mixed anxiety-depressive disorder describes patients with both anxiety and depressive symptoms who do not meet the diagnostic criteria for either an anxiety disorder or a mood disorder.• The combination of depressive and anxiety symptoms results in significant functional impairment for the affected person.• The condition may be particularly prevalent in primary care practices and outpatient mental health clinics
  24. 24. Diagnosis• anxiety and depression and the presence of some autonomic symptoms, such as tremor, palpitations, dry mouth, and the sensation of a churning stomach.
  25. 25. Clinical Features• anxiety disorders and some symptoms of depressive disorders are common symptoms of autonomic nervous system hyperactivity, such as gastrointestinal complaints, are common and contribute to the high frequency with which the patients are seen in outpatient medical clinics.
  26. 26. Treatment• the anxiolytic drugs, some data indicate that the use of triazolobenzodiazepines (e.g., alprazolam [Xanax]) may be indicated because of their effectiveness in treating depression associated with anxiety